CLINICAL AND PARACLINICAL CHARACTERISTICS OF PATIENTS WITH ADVANCED RECTAL CANCER RECEIVING TOTAL NEOADJUVANT THERAPY AT NATIONAL CANCER HOSPITAL
Main Article Content
Abstract
Objective: To describe the clinical and paraclinical characteristics of patients with advanced-stage rectal cancer undergoing total neoadjuvant therapy at National Cancer Hospital. Subjects and Methods: A descriptive study was conducted on 33 patients from October 2022 to June 2024 at National Cancer Hospital. Results: The mean age was 58,36 years, with a male-to-female ratio of 2,67:1. The majority of patients presented with bowel dysfunction symptoms, accounting for 87,9%. On endoscopy, exophytic tumors were observed in 51,5% of cases, with the most common tumor location being the mid-rectum, observed in 63,6% of patients. MRI staging of the pelvis revealed that 81,8% of patients were in stage cT3, and 84,9% were in stage cN+. The mean pre-treatment CEA level was 6,45 ng/ml. The majority of patients were in stage III before treatment, comprising 84,8% of cases. Conclusion: The study highlights specific characteristics regarding age, gender, tumor imaging on endoscopy and MRI, and pre-treatment staging in a group of rectal cancer patients undergoing total neoadjuvant therapy at National Cancer Hospital.
Article Details
Keywords
Rectal Cancer, Advanced Stage, Total Neoadjuvant Therapy
References
2. Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. Oct 2022;20(10): 1139-1167. doi:10.6004/jnccn. 2022.0051
3. Petrelli F, Trevisan F, Cabiddu M, et al. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. Annals of surgery. Mar 2020;271(3): 440-448. doi:10.1097/sla. 0000000000003471
4. Giunta EF, Bregni G, Pretta A, et al. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. Cancer treatment reviews. May 2021;96: 102177. doi:10.1016/j.ctrv. 2021.102177
5. Hà Nguyễn Thị, Kiên NX, Châu NĐ, et al. Kết quả bước đầu của điều trị tân bổ trợ toàn diện trước phẫu thuật ở bệnh nhân ung thư trực tràng giai đoạn II, III tại Bệnh viện Trung ương Quân đội 108. Tạp chí y dược lâm sàng 108. 2023;
6. Lin J, Peng J, Qdaisat A, et al. Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. Cancer treatment reviews . 2016;142:2551-2560.
7. Trung Nguyễn Thành, Xứng NV, Trung ĐHJTcYDhH. Nghiên cứu đặc điểm lâm sàng, nội soi và mô bệnh học của ung thư đại trực tràng tại bệnh viện Đà Nẵng trong 02 năm (2016-2017). Tạp chí Y dược Huế . 2018;8(8):7-12.
8. Khánh Toàn Phạm, Văn Xuân V. Đánh giá kết quả hóa xạ trị tiền phẫu ung thư trực tràng bằng kỹ thuật VMAT kết hợp Capecitabine đường uống tại Bệnh viện K. Tạp chí Y học Việt Nam. 01/12 2022;509(1)doi:10.51298/vmj.v509i1.1750
9. Hiranyakas A, Da Silva G, Wexner S, Ho YH, Allende D, Berho MJCD. Factors influencing circumferential resection margin in rectal cancer. Colorectal Disease.2013;15(3):298-303.
10. Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F, Geissler MJAr. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. Anticancer research. 2005;25(3A):1787-1793.